TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company focused on developing RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in the journal Cancers. The article reports preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The findings indicate that TTX-MC138 accumulated in metastatic bone lesions after systemic administration, reduced expression of microRNA-10b (miR-10b), increased expression of the downstream tumor-suppressor target HOXD10, and produced significant survival benefits compared with controls. Repeated dosing was well tolerated with no observed systemic toxicity.
These results are important because they further validate the company's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology. miR-10b is a well-documented biomarker of metastasis, and its overexpression is associated with aggressive tumor spread. By targeting miR-10b, TTX-MC138 aims to disrupt the metastatic process, potentially offering a new treatment option for patients with advanced cancers. The study's success in a bone metastasis model suggests that the therapy may have broad applicability across various metastatic disease settings, addressing a significant unmet medical need.
According to the press release, the findings support the potential of TTX-MC138 to treat metastatic tumors that overexpress miR-10b. The company believes that this approach could lead to improved outcomes for patients with high-risk cancers, where current treatments are often limited. The lack of observed systemic toxicity in the study is also encouraging, as it suggests that the therapy may be well tolerated in humans.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments. Its lead candidate, TTX-MC138, is being developed to treat metastatic tumors, and the company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The company's pipeline reflects a commitment to innovative approaches in oncology.
The publication in Cancers adds to the growing body of evidence supporting the potential of RNA-based therapies in oncology. As the company moves forward, it will likely need to conduct further studies to confirm these findings in clinical trials. For investors and stakeholders, this development underscores the progress being made in the fight against metastatic cancer and the potential of TransCode's technology platform.
For more information about TransCode Therapeutics and its pipeline, visit the company's newsroom at https://ibn.fm/RNAZ.
